The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinicopathological and molecular characteristics of early-onset stage III colon adenocarcinoma: An analysis of 25 studies with 35,713 patients in the Adjuvant Colon Cancer End Points (ACCENT) database.
 
Zhaohui Jin
Consulting or Advisory Role - Novartis (Inst); QED Therapeutics (Inst)
 
Jesse G. Dixon
No Relationships to Disclose
 
Hiral Parekh
No Relationships to Disclose
 
Frank A. Sinicrope
Stock and Other Ownership Interests - illumina
Honoraria - American Society of Clinical Oncology; Imedex
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); HalioDx (Inst); Roche (Inst); Ventana Medical Systems (Inst)
Research Funding - Ventana Medical Systems (Inst)
Patents, Royalties, Other Intellectual Property - Patent royalty related to immune markers in colon cancer. Patent jointly held between myself and Roche/Ventana Medical Systems. (Inst)
Travel, Accommodations, Expenses - ventana medical systems
 
Greg Yothers
Employment - Mountainview Pediatrics (I)
Consulting or Advisory Role - Orbus Therapeutics
 
Daniel G. Haller
Speakers' Bureau - Amgen; Exelixis; Lilly; Taiho Pharmaceutical
 
Hans Schmoll
No Relationships to Disclose
 
Aimery De Gramont
No Relationships to Disclose
 
Rachel Kerr
No Relationships to Disclose
 
Julien Taieb
Consulting or Advisory Role - Amgen; Celgene; Lilly; Merck KGaA; MSD; Pierre Fabre; Roche; SERVIER; Sirtex Medical
Speakers' Bureau - Amgen; Lilly; Merck; MSD; Pierre Fabre; Roche/Genentech; Sanofi; SERVIER
 
Eric Van Cutsem
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Biocartis; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; Halozyme; Incyte; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Taiho Pharmaceutical
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Chris Twelves
Honoraria - Eisai, daiichi, Pfizer
Speakers' Bureau - Eisai, Daiichi, Merck
Travel, Accommodations, Expenses - Eisai, MSD, Merck
 
Leonard B. Saltz
Research Funding - Taiho Pharmaceutical
 
Naohiro Tomita
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Lilly Japan; Merck; Takeda
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst)
 
Thierry Andre
Honoraria - AMGEN; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Pierre Fabre; Roche/Genentech; Sanofi; SERVIER; Ventana Medical Systems
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Clovis Oncology; GamaMabs Pharma; Gastrointestinal Cancers Advice; HalioDX; MSD Oncology; Pierre Fabre; SERVIER; Tesaro
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology; MSD Oncology; MSD Oncology; Roche; Roche/Genentech; Ventana Medical Systems
 
Amit Mahipal
Honoraria - Eisai
Consulting or Advisory Role - QED Therapeutics
Research Funding - Taiho Pharmaceutical
 
Richard M. Goldberg
Stock and Other Ownership Interests - Advanced Chemotherapy Technologies
Honoraria - Amgen
Consulting or Advisory Role - AstraZeneca; Bayer; Merck; Novartis; Taiho Pharmaceutical
Expert Testimony - Genentech/Roche; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Amgen; Merck; Merck KGaA
 
Thomas J. George
Consulting or Advisory Role - Tempus
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Seagen (Inst); Tesaro (Inst)
 
Qian Shi
Stock and Other Ownership Interests - Amgen; Johnson & Johnson; Merck
Consulting or Advisory Role - Boehringer Ingelheim; Yiviva
Research Funding - Celgene (Inst); Roche/Genentech (Inst)